BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:427-37. [DOI: 10.1097/01.cad.0000127330.21686.26] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2005;32:980-989. [PMID: 16032439 DOI: 10.1007/s00259-005-1859-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
2 Knight SR, Friend PJ, Morris PJ. Role of transplantation in the management of hepatic malignancy. British Journal of Surgery 2007;94:1319-30. [DOI: 10.1002/bjs.5968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
3 Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, Sun HC, Wang BL, Wang JH. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys. 2005;63:1067-1076. [PMID: 15913915 DOI: 10.1016/j.ijrobp.2005.03.058] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 3.9] [Reference Citation Analysis]
4 Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, Haj Mirzaian A, Najafi S, Shakiba M, Jalali AH. Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. Hepat Mon 2014;14:e25792. [PMID: 25737732 DOI: 10.5812/hepatmon.25792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, Delis S, Gouliamos A, Kelekis D. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269-280. [PMID: 17999110 DOI: 10.1007/s00270-007-9226-z] [Cited by in Crossref: 162] [Cited by in F6Publishing: 151] [Article Influence: 10.8] [Reference Citation Analysis]
6 Wadler S. Thalidomide for advanced hepatocellular carcinoma: Is this a real alternative? Cancer 2005;103:1-4. [DOI: 10.1002/cncr.20731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
7 Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-melman M, Chapman WC, Crippin JS. Hepatic Arterial Chemoembolization for Hepatocellular Carcinoma: Comparison of Survival Rates with Different Embolic Agents. Journal of Vascular and Interventional Radiology 2005;16:1661-6. [DOI: 10.1097/01.rvi.0000182160.26798.a2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
8 Lambert B, De Ridder L, De Vos F, Slegers G, de Gelder V, Van de Wiele C, Thierens H. Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma. Can J Physiol Pharmacol 2006;84:1021-8. [PMID: 17218968 DOI: 10.1139/y06-055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
9 Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 2012;17:725-31. [PMID: 22511263 DOI: 10.1634/theoncologist.2011-0372] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
10 Liao M, Huang J, Zhang T, Wu H. Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68453. [PMID: 23844203 DOI: 10.1371/journal.pone.0068453] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
11 Ma Y, Duan L, Li L, Lu W, Li B, Chen X. 131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment. J Gastrointest Oncol 2021;12:762-9. [PMID: 34012664 DOI: 10.21037/jgo-21-105] [Reference Citation Analysis]
12 Chen S, Yu W, Zhang K, Liu W, Chen Q. Transarterial chemoembolization for unresectable hepatocellular carcinoma: A comparison of the efficacy and safety of 2 embolic agents. Medicine (Baltimore) 2018;97:e10832. [PMID: 29794774 DOI: 10.1097/MD.0000000000010832] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Liu S, Li H, Guo L, Zhang B, Zhou B, Zhang W, Zhou J, Fan J, Ye Q. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. Oncologist. 2019;24:513-520. [PMID: 30552155 DOI: 10.1634/theoncologist.2018-0305] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
14 Liao M, Zhu Z, Wang H, Huang J. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol. 2017;52:624-634. [PMID: 28276833 DOI: 10.1080/00365521.2017.1292365] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
15 Cheng HY, Wang XY, Zhao GL, Chen D. Imaging findings and transcatheter arterial chemoembolization of hepatic malignancy with right atrial embolus in 46 patients. World J Gastroenterol 2008; 14(22): 3563-3568 [PMID: 18567087 DOI: 10.3748/wjg.14.3563] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
16 Gunvén P. Liver embolizations in oncology: A review: Part I. Arterial (chemo)embolizations. Med Oncol 2008;25:1-11. [DOI: 10.1007/s12032-007-0039-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
17 Sze DY. Targeted Drug Delivery for Refractory Hemorrhagic Crohn Disease. Journal of Vascular and Interventional Radiology 2006;17:163-7. [DOI: 10.1097/01.rvi.0000183192.01135.b1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Liao M, Huang J, Zhang T, Wu H. Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68453. [PMID: 23844203 DOI: 10.1371/journal.pone.0068453pone-d-13-13354] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
20 Koçyiğit A, Dicle O, Göktay Y, Astarcıoğlu I. The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol. Diagn Interv Radiol 2014;20:323-9. [PMID: 24808440 DOI: 10.5152/dir.2014.13462] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Low MJ. Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab. 2004;18:607-622. [PMID: 15533778 DOI: 10.1016/j.beem.2004.08.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
22 Ghanaati H, Alavian SM, Jafarian A, Ebrahimi Daryani N, Nassiri-Toosi M, Jalali AH, Shakiba M. Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence. Iran J Radiol. 2012;9:167-177. [PMID: 23407596 DOI: 10.5812/iranjradiol.8242] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
23 Grégory J, Créquit P, Vilgrain V, Boutron I, Ronot M. Published trials of TACE for HCC are often not registered and subject to outcome reporting bias. JHEP Rep 2021;3:100196. [PMID: 33490934 DOI: 10.1016/j.jhepr.2020.100196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Petruzzi NJ, Frangos AJ, Fenkel JM, Herrine SK, Hann HW, Rossi S, Rosato EL, Eschelman DJ, Gonsalves CF, Brown DB. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma. J Vasc Interv Radiol 2013;24:266-73. [PMID: 23261143 DOI: 10.1016/j.jvir.2012.10.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]